Cardiovascular Systems, Inc. Unveils New Data from CONFIRM Study Series at the New Cardiovascular Horizons Conference

Published: Jun 06, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), unveiled new data from its CONFIRM study series in three poster presentations at the 2013 New Cardiovascular Horizons (NCVH) conference in New Orleans. Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), unveiled new data from its CONFIRM study series in three poster presentations at the 2013 New Cardiovascular Horizons (NCVH) conference in New Orleans.

The CONFIRM study series evaluated the use of CSI’s orbital atherectomy system as a treatment for peripheral arterial disease (PAD)—in above- and below-the-knee lesions—in a real world population of patients (with no exclusions).

Help employers find you! Check out all the jobs and post your resume.

Back to news